Citations

Clear

3138 citation(s) found for "Smith, AM".

Every Centiloid, from Everywhere, All at Once
Snyder, Heather M. , Apostolova, Liana G., Bombois, Stéphanie, Bourgeat, Pierrick, Braskie, Meredith N. , Carrillo, Maria, Casaletto, Kaitlin B, Chang, C. -C., Chang, Hsin‐I., Chao, Yishu , Chetelat, Gaël, Collij, Lyduine E., Dickerson, Brad C., Dubois, Bruno, Valdez, Alfonso Fajardo, Farrar, Gill , Fortea, Juan M., Frisoni, Giovanni B, Gu, Yuna , Guo, Tengfei, Hansson, Oskar H., Huang, Q., Huang, Shu‐Hua , Ishii, Kenji, Jagust, William J., Kato, Takashi , Koeppe, R. A., Kramer, Joel H, Landau, Susan M., Landeau, Brigitte, Lee, Sangwon, Lopresti, Brian J. , Lowe, Val J. , Mao, Xiaoxie, March, Andrew, Masters, Colin L., Mézenge, Florence, Mormino, Elizabeth C. , Franquesa‐Mullerat, María , Nakamura, Akinori, O'Bryant, Sid E., Pappas, Ioannis G., Rowe, C. C., Schott, Jonathan M, Schwartz, Daniel L. , Schwarz, Christopher G, Seo, Sang Won, Shekari, Mahnaz, Smith, Ruben, Sokołowski, Andrzej , Soleimani‐Meigooni, David, Sperling, Reisa A., Sun, Pan , Toga, Arthur W., Vaillancourt, David E. , Flier, Wiesje M. van der, Vemuri, Prashanthi, Villain, Nicolas , Villemagne, Victor L., Villeneuve, Sylvia , Wang, Wei‐En, Weiner, Michael S. W., Xiao, Cally , Xie, Fang, Yoon, Yeojun, Yun, M R , Rabinovici, Gil D., Wang, Wei‐en , Blazhenets, Ganna , Apostolova, Liana G. , Asken, Breton M. , Bejanin, Alexandre , Bombois, Stéphanie , Bourgeat, Pierrick , Casaletto, Kaitlin B. , Cash, David M. , Chang, Hsin‐I , Chételat, Gaël , Coath, William , Collij, Lyduine , Colmant, Lise , Dickerson, Brad C., Dubois, Bruno , Fortea, Juan , Frisoni, Giovanni B. , Gardner, Raquel C. , Garibotto, Valentina , Guo, Tengfei , Hanseeuw, Bernard , Hansson, Oskar , Harrison, Theresa M. , Ishii, Kazunari , Jagust, William J. , Kramer, Joel H. , Landau, Susan, Landeau, Brigitte , Masters, Colin L. , Mézenge, Florence, Nakamura, Akinori , O’Bryant, Sid E. , Peretti, Débora Elisa , Quenon, Lisa , Salvadó, Gemma , Schott, Jonathan M. , Schwarz, Christopher G. , Seo, Sang Won , Shekari, Mahnaz , Silbert, Lisa C. , Sokolowski, Andrzej, Soleimani‐Meigooni, David N. , Sperling, Reisa Anne , Sun, Pan , Toga, Arthur W. , Giessen, Elsmarieke van de , Flier, Wiesje M. van der , Vemuri, Prashanthi , Villemagne, Victor L. , Weiner, Michael W. , Xie, Fang , Young, Christina B. , Rabinovici, Gil D. , Joie, Renaud La

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_110011 Get It

Abstract Background Ten years after the original publication, the Centiloid framework is now broadly used to harmonize amyloid‐PET quantification, facilitate data sharing and comparison across cohorts, and even assist visual interpretation in clinical settings. We evaluated the global implementation of Centiloids by comparing their distribution and corresponding positivity thresholds across cohorts. Methods We gathered data from publicly available cohorts and reached out to investigators across the world to collect cross‐sectional Centiloids, demographic and clinical information, and visual read data. Gaussian mixture models (GMM, k=2) were fitted to Centiloid values for each cohort and cutoffs were calculated as mean + 2SD of the lower Gaussian. When visual reads were available, we determined Centiloid cutoffs that maximized correspondence with visual reads (Cohen’s kappa). Data was combined across cohorts using random effects meta‐analyses. Results As of January 2025, we included 37 cohorts ( n = 41,678 participants) with heterogeneous pipelines, radiotracers, and clinical and demographic characteristics (Table‐1). The low Gaussian peaks ranged from ‐9 to 10CL; the meta‐analysis identified a common peak at 1CL. The second peaks were more heterogeneous (range=38‐102CL; meta‐analysis outcome=64CL). Across cohorts, the proportion of cognitively unimpaired versus impaired participants impacted the position of both peaks, with better separation in cohorts enriched in impaired individuals (Figure‐1C). The meta‐analysis indicated a GMM‐based cutoff of 19CL (95%CI: 16‐21CL, Figure‐1B); subgroup analyses showed no evidence of significant effect between single versus multicenter settings (17 versus 20CL, p = 0.30), MRI‐based or PET‐only processing (18 versus 19CL, p = 0.88), and no evidence of difference across radiotracers (Flutemetamol: 16CL; PIB: 17CL, Flutafuranol: 18CL, Florbetaben: 19CL, Florbetapir: 20CL, p = 0.78). In a subset of 29,496 participants with visual reads available, binary visual reads corresponded well to Centiloids (common kappa=0.86, Figure‐2A). The visual read‐based cutoff of 24CL (95%CI: 21‐27CL, Figure‐2B) maximized correspondence between visual read and quantification and was slightly higher than the GMM‐based cutoff. All meta‐analysis models showed high non‐random heterogeneity (I 2 >80%) across studies, suggesting non‐random differences in peaks and cutoffs. Conclusions Meta‐analysis‐based cutoffs align well with thresholds from the existing literature. High heterogeneity among studies underscores the need to investigate contributing factors, raising concerns about applying common cutoffs.
External Validation of Joint Propagation Model‐Based Tau PET CenTauR units
Leuzy, Antoine , Raket, Lars Lau, Villemagne, Victor L., Klein, Gregory , Tonietto, Matteo, Olafson, Emily, Baker, Suzanne L. , Saad, Ziad S., Bullich, Santiago , Lopresti, Brian J. , Sanabria, Sandra , Boada, Mercè, Charil, A., Collins, Emily C., Collins, Jessica, Gunn, Roger N. , Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Insel, Philip S., Irizarry, Michael C., Jack, C. R., Jagust, William J., Johnson, Keith A., Johnson, Sterling C., Karten, Yashmin, Marquié, Marta, Mathotaarachchi, Sulantha , Mintun, Mark A., Huang, Q., Mao, Xiaxie, Gnörich, Johannes , Pappas, Ioannis, Petersen, Ronald, Schwarz, Christopher G, Smith, Ruben, Stephens, Andrew , Whittington, Alex , Carrillo, Maria, Pontecorvo, Michael J. , Haeberlein, Samantha Budd , Dunn, Billy , Kolb, H., Stephenson, Diane , Tatton, Nadine , Brendel, M., Xie, Fang, Hansson, Oskar H., Rial, Alexis Moscoso , Rakêt, Lars Lau , Villemagne, Victor L. , Tonietto, Mattéo , Olafson, Emily, Lutz, Olivia , Boada, Merce , Betthauser, Tobey J. , Collins, Emily C. , Higuchi, Makoto, Hutchison, R. Matthew , Iaccarino, Leonardo , Insel, Philip S. , Irizarry, Michael C. , Jack, Clifford R. , Jagust, William J. , Johnson, Keith A. , Johnson, Sterling C. , Marquié, Marta , Ossenkoppele, Rik , Pappas, Ioannis , Petersen, Ronald, Chiotis, Konstantinos , Rabinovici, Gil D. , Rosa-Neto, Pedro , Schwarz, Christopher G. , Kolb, Hartmuth C. , Brendel, Matthias , Rowe, Christopher Cleon , Hansson, Oskar , Doré, Vincent

Mayo Clinic

Alzheimer's & Dementia | December 23, 2025 | Volume: 21 | Issue: S8 | Pages: No page available

10.1002/alz70862_109722 Get It

Abstract Background The Joint Propagation Model (JPM)‐based CenTauR scale was recently introduced to harmonize tau‐PET quantification across different radiotracers. This study examined how CenTauR harmonization enhances the comparability of tau‐PET quantification across matched cohorts using different tracers. The evaluation focused on three key aspects: (1) comparing tau‐PET positivity rates as defined by CenTauR, (2) evaluating its diagnostic accuracy for symptomatic AD, and (3) analyzing longitudinal changes in tau‐PET rates over time. Method The JPM, developed by the CPAD‐led Tau PET Harmonization Working Group (Leuzy et al., Alzheimers Dement. 2024; Figure 1A), models relationships between anchor point subjects and head‐to‐head tau‐PET SUVR data onto the CenTauR scale, providing conversion equations for multiple tracers. JPM equations were applied to [¹⁸F]flortaucipir SUVR (Meta‐temporal ROI) data from 561 cognitively impaired participants in the ADNI and OASIS‐3 studies. Using ROC analysis, we determined the CenTauR cut‐off for positivity (T+) that maximized the Youden index for discriminating between FDA‐approved positive/negative visual reads. Three separate cohorts, scanned using [¹⁸F]flortaucipir (ADNI), [¹⁸F]MK‐6240 (CPAS), and [¹⁸F]RO‐948 (BioFINDER‐2), were matched 1:1 by age, MMSE, amyloid‐β, and clinical diagnosis. CenTauR‐based metrics were compared across these cohorts. Result A cut‐off of 18 CenTauRs was found to optimally classify [ 18 F]flortaucipir PET visual reads (Figure 1B). The matching procedure identified 1089 participants (363 per cohort). The frequency of T+ using the 18 CenTauRs cut‐off for the Meta‐Temporal ROI was highly comparable across tracers across groups, except for the Aβ‐positive cognitively unimpaired group, where variability was more pronounced due to a smaller sample size (Figure 2A). Similarly, tau‐PET discriminative accuracy for symptomatic AD vs controls remained similar across [ 18 F]flortaucipir and [ 18 F]MK‐6240 (Figure 2B). In a separate sample of 212 matched participants from ADNI ([¹⁸F]flortaucipir) and AIBL ([¹⁸F]MK‐6240) with baseline and 1‐year follow‐up tau‐PET scans, 1‐year change in CenTauRs was comparable (Figure 2C). An exploratory voxelwise transformation, utilizing the Meta‐Temporal conversion equation in a representative case scanned with both [¹⁸F]flortaucipir and [¹⁸F]MK‐6240, demonstrates the potential for voxelwise CenTauR harmonization (Figure 3). Conclusion These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. Additional validation analyses with larger cohorts including other radiotracers ([¹⁸F]PI‐2620) are underway.
Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors
Draper, Nicole, Connelly‐Smith, Laura , Alquist, Caroline R. , Fernando, Leonor P. , Jones, Andrew R. , Schmidt, Amy E. , Harmon, Charles S., Lee, Esther , Linnik, Yevgeniy , Cooling, Laura , Godbey, Elizabeth A, Cooling, Laura , Godbey, Elizabeth A. , Schwartz, Joseph E. , Jones, Andrew, Harmon, Charles

Mayo Clinic

Journal of Clinical Apheresis | December 20, 2025 | Volume: 40 | Issue: 6 | Pages: No page available

10.1002/jca.70074 | PMID 41420827 Get It

ABSTRACT Plerixafor (PLX) is FDA approved for use in autologous peripheral blood stem cell donors but not in allogeneic donors. This study was completed by members of the ASFA HPC Donor Subcommittee to examine the incidence and characteristics of poor mobilizers (PM) among matched related donors (MRD), as well as factors associated with PLX use in MRD. Risks of poor mobilization in MRD were older age, especially donors older than 60 years, lower baseline platelet counts, and heavier recipients. PLX use in PM was low but safe, tripling the success rate for collection. This study adds evidence to the body of literature to support use of PLX in allogeneic donors who are PM.
Safety of selective operating room extubation after median sternotomy for cardiac surgery with parasternal regional analgesia
Christensen, Jon M. , Ripoll, Juan G, Vinzant, Nathan J, Smith, Mark, Mauermann, William J, Dearani, Joseph A, Lemahieu, Allison M, Schroeder, Darrell R, Ritter, Matthew, Christensen, Jon , Ripoll, Juan G, Vinzant, Nathan J, Smith, Mark, Mauermann, William J, Dearani, Joseph A, Lemahieu, Allison M, Schroeder, Darrell R, Ritter, Matthew

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107157

10.1136/rapm-2025-107157 | PMID 41419242 Get It

Introduction The safety of operating room extubation (ORE) immediately following cardiac surgery via median sternotomy remains unclear. However, reported outcomes in the setting of parasternal regional analgesia are limited. This study examined the safety of ORE for patients who received postoperative superficial parasternal intercostal plane (SPIP) blocks following median sternotomy for cardiac surgery. Methods Single-center retrospective cohort study from January 2020 to September 2023 compared the outcomes of adult cardiac surgical patients who were either extubated in the operating room immediately after surgery with SPIP blocks (ORE-B), received SPIP blocks and were extubated in the intensive care unit within 6 hours (FTE-B) or did not receive SPIP blocks and were extubated in the intensive care unit within 6 hours (FTE). Assessed outcomes were reintubation, use of non-invasive positive pressure ventilation (NIPPV), intensive care unit (ICU) readmission, return to OR, postoperative transfusion, ICU and hospital length of stay. Results 2294 patients were studied, which included 256 ORE-B patients, 729 FTE-B patients and 1,309 FTE patients. Differences in reintubation rates (1.2% vs 0.7% vs 1.2%, all p≥0.26) and use of NIPPV (4.8% vs 4.8% vs 5.1%, all p≥0.743) did not differ between ORE-B, FTE-B, and FTE groups, respectively. Time to extubation differed between FTE-B and FTE groups (2.5 hours vs 3.8 hours, p=<0.001), respectively. Additionally, hospital length of stay was significantly shorter for groups ORE-B and FTE-B compared with group FTE (5 days vs 5 days vs 6 days), respectively. Conclusions Selective ORE after median sternotomy for cardiac surgery was not associated with an increased risk of reintubation and NIPPV use in the setting of parasternal regional analgesia.
Epigenomic study of the lower airway reveals COPD-associated methylation patterns and potential microbiota links
Cao, Sudan , Shrivastav, Abhishek, Bleecker, Eugene R., Madapoosi, Siddharth , Erb‐Downward, John R. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Barjaktarević, Igor , Bowler, Russell, Barr, Robert, Comellas, Alejandro P. , Cooper, Christopher B. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Moore, Wendy C. , O’Neal, Wanda K. , Paine, Robert , Smith, Benjamin M. , Hoffman, Eric A. , Meyers, Deborah A. , Woodruff, Prescott G. , Christenson, Stephanie A. , Ortega, Victor E. , Cao, Shuo , Chen, Xianfeng , Barjaktarevic, Igor , Comellas, Alejandro P , Han, MeiLan King , Kim, Victor , Huang, Yvonne J , O'Neal, Wanda K , Hoffman, Eric A , Christenson, Stephanie A , Chen, Xianfeng, Couper, David , Kaner, Robert J. , Martínez, Fernando J. , Curtis, Jeffrey L.

Mayo Clinic

BMJ Open Respiratory Research | December 19, 2025 | Volume: 12 | Issue: 1 | Pages: e003572

10.1136/bmjresp-2025-003572 | PMID 41419234 Get It

Introduction Despite the identification of multiple susceptibility loci by genome-wide association studies (GWAS), considerable chronic obstructive pulmonary disease (COPD) heritability remains unexplained. Aim To identify interaction networks of airway epithelial cell DNA methylation in COPD and further explore potential correlations with airway bacterial composition, as potentially collective regulators of biological pathways influencing COPD severity. Methods Using DNA isolated from bronchial airway brushings of 67 ever-smokers (>20 pack-years) from the SubPopulations and InteRmediate Outcomes Measures in COPD Study (SPIROMICS), we assessed proportion of DNA methylation (β) by epigenome-wide association study (EWAS) and examined associations of differentially methylated CpG probes (DMPs) with risk for moderate-to-severe COPD (N=34) versus absent or mild COPD (N=33). We tested co-methylation modules generated by Weighted Correlation Network Analyses (WGCNA) for associations with moderate-to-severe COPD and with bacterial genus-level relative abundances (16S rRNA sequencing). Results EWAS-identified nominally significant DMPs enriched for lung function GWAS loci. Eigengenes in six WGCNA modules were associated with moderate-to-severe COPD (false discovery rate <0.05). Four of those modules were enriched for forced expiratory volume in 1 s/forced vital capacity GWAS loci, and five overlapped with DMPs from EWAS. Overlapping CpG loci in three COPD-associated modules were adjacent to mucin genes; one had 10 genes highly ranked by connectivity with MUC5B, including important pathway genes: B3GNT6 , DGKI and ITGA8 . CpGs in an independent COPD-associated module showed the most correlations with Rothia , with directionality suggestive of negative associations with moderate-severe COPD. Conclusions Bronchial epithelial DNA methylation modules enriched for lung function GWAS loci associate with COPD severity in SPIROMICS. Potential module relationships to bronchial bacterial composition require further validation.
Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab
Romich, Ellen , Baker, Joshua F. , Riley, Thomas R. , Green, Ian , Rhee, Rennie L. , McAlear, Carol A. , Specks, Ulrich , Smith, Rona , Jayne, David , Merkel, Peter A. , Investigators, for the RITAZAREM, Moreland, Larry W. , Nachman, Patrick H. , Smith, Rona M , Jayne, David , Moreland, Larry W , Specks, Ulrich , Merkel, Peter A , Baker, Joshua F , Investigators, for the RITAZAREM

Mayo Clinic

Arthritis & Rheumatology | December 19, 2025 | Volume: 78 | Issue: 5 | Pages: 1134-1144

10.1002/art.70025 | PMID 41412975 Get It

Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial. Patients aged 15 years or older with AAV and a positive test for anti–proteinase‐3 or anti‐myeloperoxidase‐ANCA who achieved remission after reinduction with rituximab and glucocorticoids were randomized at month 4 to receive continued rituximab or azathioprine for a maintenance period up to 24 months, followed by observation until relapse or up to 48 months. Generalized estimating equations logistic regression identified baseline and time‐varying risk factors for relapse by the next visit for the two study phases: maintenance (months 4–24) and off‐treatment (months 24–48). Results Among 170 patients (median [interquartile range] age 59 [48–68] years, disease duration 5 [2–10] years), 99 relapses occurred (46 during maintenance). During maintenance, musculoskeletal involvement (odds ratio [OR]: 2.8, 95% confidence interval [CI]: 1.1–7.2; P = 0.03) and higher patient global assessment (OR: 1.1, 95% CI: 1.0–1.2; P = 0.04) were associated with relapse. During the off‐treatment phase, presence of CD19 + B cells (OR: 2.5, 95% CI: 1.2–5.1; P = 0.01) and reappearance of ANCA (OR: 3.2, 95% CI: 1.3–7.7; P = 0.01) were each associated with higher relapse risk. Multivariable analysis identified markers of inflammation (changes in platelets, white blood cells, and IgA) associated with relapse. Conclusion Risk factors for relapse in AAV vary by treatment phase. Monitoring markers of inflammation and immune reconstitution may identify patients at risk for relapse, particularly after treatment withdrawal.
Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Pérez-Millan, Agnès , Falgàs, Neus , Borrego-Écija, Sergi, Antonell, Anna, Fernández-Villullas, Guadalupe, Esteller-Gauxax, Diana, Tort-Merino, Adrià, Bargalló, Núria, Balasa, Mircea, Lladó, Albert, Chrem, Patricio, Day, Gregory S. , Devenney, Emma , Huey, Edward D. , Ikeuchi, Takeshi, Jucker, Mathias, Roh, Jee Hoon , Vitali, Paolo , Ortíz, Ana Luisa Sosa, Llibre-Guerra, Jorge J, Gordon, Brian A., Sánchez-Valle, Raquel, (DIAN), The Dominantly Inherited Alzheimer Network, Daniels, Alisha , Courtney, Laura, Ziegemeier, Angela, Skrbec, Karina, Hellm, Cortaiga, Martin, Mariana , Ziegemeier, Ellen , Bartzel, Jamie, Xiong, Chengie , Xu, Xiong, Lu, Ruijin, Li, Yan , Nie, Yuzheng , Gremminger, Emily, Perrin, Richard J. , Franklin, Erin , Ibanez, Laura, Jerome, Gina, Stauber, Jennifer, Baker, Bryce, Minton, Matthew, Cruchaga, Carlos C, Goate, Alison M, Renton, Alan E, Picarello, Danielle M. , Benzinger, Tammie L S, Hornbeck, Russ C. , Chen, Allison, Chen, Charles D., Flores, Shaney, Joseph-Mathurin, Nelly, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Wang, Qing, Sabaredzovic, Edita, Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Vlassenko, Andrei G. , Wang, Yong, Hassenstab, Jason, Smith, Jennifer, Stout, Sarah, Marsh, Jacob, Morris, John C, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Graff-Radford, Neill R, Farlow, Martin R. , Chhatwal, Jasmeer P. , Maa, Courtney, Ishiguro, Takanobu , Ishii, Kenji, Senda, Michio, Salloway, Stephen , Bechara, Jacob A, Martins, Ralph, Fox, Nick C, Ryan, Natalie S. , Laske, Christoph , Timofejavaite, Reda, Kuder-Buletta, Elke, Graber-Sultan, Susanne, Obermueller, Ulrike, Xiong, Chengjie , Rödenbeck, Yvonne, Vӧglein, Jonathan, Méndez, Patricio Chrem, Vazquez, Silvia, Leon, Yudy Milena, Ramirez, Laura, Baena, Ana , Bocanegra, Yamile , Levey, Allan, Johnson, Erik C B, Seyfried, Nicholas T. , Ringman, John M. , Fagan, Anne M. , Mori, Hiroshi, Lopera, Francisco , Goate, Alison , Hassenstab, Jason , Borrego‐Écija, Sergi , Pérez‐Millan, Agnès , Ikeuchi, T , Vöglein, Jonathan , Roh, Jee Hoon , Vitali, Paolo , Gordon, Brian A , Bateman, Randall J , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Borrego-Écija, Sergi , Goate, Alison M , Bosch, Beatríz , Antonell, Anna, Fernández‐Villullas, Guadalupe , Esteller, Diana , Tort‐Merino, Adrià , Balasa, Mircea , Lladó, Albert , Aguillon, David , Ikeuchi, Takeshi , Jucker, Mathias , Kasuga, Kensaku , Vöglein, Jonathan , Llibre‐Guerra, Jorge J. , Gordon, Brian A. , McDade, Eric , Bateman, Randall J. , Sánchez‐Valle, Raquel , Supnet, Charlene , Lu, Ruijin, Wang, Guoqiao , Ibanez, Laura , Cruchaga, Carlos , Fulton‐Howard, Brian , Banks, Jessica N , Flores, Shaney , Goyal, Manu S. , Hobbs, Diana A. , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wang, Yong , Smith, Jennifer, Stout, Sarah H., Aschenbrenner, Andrew J. , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Berman, Sarah , Graff‐Radford, Neill R. , Senda, Michio , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Bechara, Jacob , Cash, David M. , Laske, Christoph , Fougère, Christian la , Reischl, Gerald , Lee, Jae Hong , Allegri, Ricardo , Surace, Ezequiel , Vazquez, Silvia, Ramírez, Laura, Serna, Laura, Johnson, Erik C. B. , Masters, Colin L. , Noble, James M. , Lopera, Francisco Javier

Mayo Clinic

Brain Communications | December 18, 2025 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcaf488 | PMID 41523185 Get It

Abstract The cortical asymmetry index evaluates the cortical thickness asymmetry between hemispheres. We investigated cortical asymmetry index in asymptomatic and symptomatic mutation carriers of autosomal dominant Alzheimer’s disease to explore the brain asymmetry within the Alzheimer’s disease continuum. Sixty baseline T1-weighted MRI scans were obtained from the Clinic Barcelona cohort. Baseline and longitudinal MRI data from 564 participants within the dominantly inherited Alzheimer network observational study were used as an independent, confirmatory cohort. Cerebrospinal fluid and plasma neurofilament light chain levels were included when available. Cortical thickness was calculated using Freesurfer and cortical asymmetry index was calculated via an open-source pipeline. Cross-sectional analyses examined cortical asymmetry index differences based on clinical classification and APOE ε4 status, adjusting for age, sex and estimated years from onset, while correlations were assessed with age, estimated years from onset, mini-mental state examination scores, and neurofilament light. Longitudinal cortical asymmetry index evolution was modelled using generalized additive models in the dominantly inherited Alzheimer network observational study cohort, incorporating age, sex, and the interaction between group and estimated years from onset. The cortical asymmetry index successfully distinguished asymptomatic mutation carrier and symptomatic mutation carriers from healthy controls in the Clinic Barcelona cohort and symptomatic mutation carriers from controls in dominantly inherited Alzheimer network observational study. Higher cortical asymmetry index in mutation carriers (asymptomatic mutation carrier and symptomatic mutation carriers combined) and in symptomatic mutation carriers were associated with higher plasma neurofilament light levels, a closer proximity to symptom onset, and lower mini-mental state examination in the Clinic Barcelona cohort. In the dominantly inherited Alzheimer network observational study cohort, mutation carriers exhibited increased cortical asymmetry index compared to controls and correlated with elevated neurofilament light (plasma and Cerebrospinal fluid), lower mini-mental state examination, and a closer proximity to symptom onset. APOE3/3 carriers showed greater asymmetry than other APOE genotypes and significant cortical asymmetry index differences between asymptomatic mutation carrier and symptomatic mutation carriers. Longitudinally, cortical asymmetry index increased over time significantly in symptomatic mutation carriers. These findings underscore brain asymmetry as a potential biomarker for early Alzheimer’s disease progression in autosomal dominant Alzheimer’s disease, with implications for detection and monitoring tracking disease-related neuroanatomical changes.
Hemodynamic Progression of Adult Valvular Aortic Stenosis
Amy, SW, Holmes, David R. , Smith, Hugh C., Connolly, Daniel C., Hynes, Janey, Ilstrup, Duane M., Danielson, Gordon K., Ng, Amy S.H.

Mayo Clinic

Catheterization and Cardiovascular Diagnosis | December 17, 2025 | Volume: 12 | Issue: 3 | Pages: 145-150

10.1002/j.1097-0304.1986.tb00002.x Get It

Hemodynamic progression of valvular aortic stenosis was studied in 54 patients who had serial cardiac catheterizations. There were 47 men and 7 women with a mean age of 61.2 years. The time interval between studies was 4.4 years (range, 0.4‐12.2). Associated coronary artery disease was present in 37 patients (69%). The initial mean aortic valve area (Hakki's formula) was 1.26 cm 2 (range, 0.66‐2.85), and the aortic valve area at last follow‐up was 0.77 cm 2 (range, 0.29‐1.95), with mean reduction of 0.49 cm 2 . The mean peak systolic gradient increased from 23.3 ± 15.1 mm Hg at initial study to 52.6 ± 27.5 mm Hg at last study, a mean increase of 29.3 ± 23.6 mm Hg. Patients with no or mild left ventricular impairment and no or mild coronary artery disease are more likely to have progression than patients with more severe left ventricular impairment or coronary artery disease (P < 0.05). Aortic valve replacement for progressive aortic stenosis was required at a later date after coronary artery bypass grafting in a small group of nine patients. In this small group, there was a high intraoperative mortality of 33%.
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
Gore, John L. , Wolff, Erika M. , Nash, Michael G. , Comstock, Bryan A. , Gilbert, Scott M. , Chang, Sam S., Chisolm, Stephanie , MacLean, Douglas B., Wright, Jonathan L. , Kates, Max , Pohar, Kamal S. , Guzzo, Thomas J., Bivalacqua, Trinity J, Nepple, Kenneth G. , Montgomery, Jeffrey S., Scarpato, Kristen R., Master, Viraj A. , Chen, David YT , Mossanen, Matthew , O’Neil, Brock , Tyson, Mark D. , Mansour, Ahmed M. , Chamie, Karim, Riggs, Stephen B. , Kukreja, Janet Baack , Peyton, Cheri L. , Nix, Jeffrey W. , Dickstein, Rian, Sankin, Alex , Lane, Brian R. , Bassett, Jeffrey C. , Patel, Sanjay , Lee, Eugene K. , Ritch, Chad R. , Follmer, Kristin , Kim, Sung Min , Kessler, Larry G. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J., Catto, James W.F. , Sankin, Alexander , Woldu, Solomon L , Master, Viraj A , Chen, David Y T , Daneshmand, Siamak , O'Neil, Brock B , Westerman, Mary E , Kamat, Ashish M. , Modi, Parth K , Peyton, Charles C , Gadzinski, Adam J , Shore, Neal , Patel, Sanjay , Ritch, Chad R , Follmer, Kristin M , Kim, Sung Min , Kessler, Larry G , Bivalacqua, Trinity J. , Daneshmand, Siamak , Westerman, Mary E. , Garg, Tullika K. , Shore, Neal D. , Morris, David S. , Macleod, Liam Connor , Lee, Jenney R. , Smith, Angela B. , group, on behalf of the CISTO Collaborative, Gore, John L., Smith, Angela B., Wolff, Erika M., Comstock, Bryan A., Nash, Michael G., Follmer, Kristin M., Lee, Jenney R., Kim, Sung Min, Kessler, Larry G., Gilbert, Scott M., Chang, Sam S., Wright, Jonathan L., Kates, Max R., Pohar, Kamal S., Guzzo, Thomas J., Bivalacqua, Trinity J., Nepple, Kenneth G., Montgomery, Jeffrey S., Scarpato, Kristen R., Woldu, Solomon L., Master, Viraj A., Chen, David Y.T., Mossanen, Matthew, Daneshmand, Siamak, O'Neil, Brock B., Tyson, Mark D., Westerman, Mary E., Kamat, Ashish M., Mansour, Ahmed M., Chamie, Karim, Riggs, Stephen B., Kukreja, Janet B., Modi, Parth K., Garg, Tullika, Peyton, Charles C., Nix, Jeffrey W., Dickstein, Rian, Gadzinski, Adam J., Sankin, Alex, Shore, Neal D., Lane, Brian R., Bassett, Jeffrey C., Patel, Sanjay, Morris, David S., Macleod, Liam C., Lee, Eugene K., Ritch, Chad R., Chisolm, Stephanie, MacLean, Douglas B., Almeida, Fred, Murray, Mary Beth Ballard, Lindsey, Nancy, Lipman, Robert, Oliver, Richard M., Roscoe, Lori A., Sachse, Karen, Lotan, Yair, Porten, Sima P., Taylor, Jennifer M., Steinberg, Gary D., Catto, James W.F., Downs, Tracy M., Malin, Jennifer L., Davicioni, Elai, Rios, Patricia, Yano, Marielle, Jun, Grace, Li, Casey, Nefcy, Christopher, Basu, Anirban, Heagerty, Patrick J.

Mayo Clinic

Journal of Clinical Oncology | December 15, 2025 | Volume: 44 | Issue: 4 | Pages: 274-285

10.1200/jco-25-01324 | PMID 41397208 Get It

PURPOSE To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer–specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Freeman, Ciara L. , Garcés, Juan-José, Lee, Holly , Papadimitriou, Marios , Silva, Ariosto Siqueira , Füller, Etta Rozen , Agius, Phaedra , Hansen, Doris K., Zhao, Xiaohong , Meads, Mark B. , Teer, Jamie K. , Hagner, Patrick R. , Alsina, Melissa , Ramasubramanian, Anusuya , Smith, Eric L. , Mailankody, Sham , Chesi, Marta, Hamadeh, Issam S. , Shain, Kenneth H. , Ilundain, Marta Larrayoz , Durante, Michael , Sharik, Meaghen E. , Du, Megan T. , Hagner, Patrick, Bergsagel, P. Leif , Landgren, C Ola , Maura, Francesco , Maclachlan, Kylee , Larráyoz, Marta , Ziccheddu, Bachisio , Meermeier, Erin W. , Garcés, Juan‐José , Durante, Michael , Firestone, Ross , Menges, Meghan A. , Reid, Kayla M. , Diamond, Benjamin , Sudalagunta, Praneeth Reddy , Leblay, Noémie , Ahn, Sungwoo , Fuller, Ethan, Briercheck, Edward L. , Hansen, Doris K. , Song, Xiaofei , Jelı́nek, Tomáš , Baz, Rachid , Smith, Eric, Giralt, Sergio , Bergsagel, P. Leif , Neri, Paola , Chesi, Marta , Martinez‐Climent, José A. , Locke, Frederick L. , Bahlis, Nizar Jacques , Landgren, Ola , Usmani, Saad Z.

Mayo Clinic

No container title available | December 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.08.692978 | PMID 41415462 Get It

ABSTRACT Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.